Response: Is there really a relationship between multidrug resistance gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia?

Blood

Volumn 116, Issue 26, 2010, Pages 6145-6146

  Dulucq, Stéphanie ^a   Preudhomme, Claude ^b   Guilhot, François ^c   Mahon, François Xavier ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; IMATINIB; PEGINTERFERON;

CHRONIC MYELOID LEUKEMIA; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MOLECULAR RESISTANCE; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 78650636695     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-298794     Document Type: Letter

References (4)

1. Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008;112(5):2024-2027.
2. Guilhot F, Preudhomme C, Guilhot J, et al. Significant higher rates of undetect-able molecular residual disease and molecular responses with pegylated form of interferon alpha2a in combination with imatinib (IM) for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients (pts): confirmatory results at 18 months of part 1 of the Spirit phase III randomized trial of the French CML Group (FI LMC) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(11): Abstract 340.
3. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-2388.
4. Kim DH, Sriharsha L, Xu W, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009;15(14):4750-4758.